Drug pricing, reimbursement and market access determine how much of a treatment’s medical promise can become commercial revenue. A company can win regulatory approval, announce a substantial price and still struggle to generate paid demand. Insurers may restrict treatment to a narrower patient group, hospitals may lack the resources to administer it, or patients may face costs that prevent them from starting. A revenue forecast needs to account for each barrier. Multiplying disease prevalence by the advertised price skips much of the work.
For biotech investors, the central question is what the manufacturer can collect from patients who actually receive treatment, after discounts and other deductions. That requires separating the price of a medicine from its coverage terms, payment arrangements and practical availability. These decisions sit within the wider economics of biotech commercialisation, but deserve their own analysis: an attractive clinical profile does not establish an attractive net price, and broad insurance coverage does not establish rapid adoption.
Pricing, Reimbursement and Market Access Are Different Decisions
Pricing concerns what a manufacturer charges and what buyers negotiate. Reimbursement concerns whether a payer will fund treatment, under which conditions and how the pharmacy or healthcare provider receives payment. Market access is broader. It includes the evidence, agreements and operational arrangements that allow an eligible patient to obtain funded treatment. These terms overlap, but they are not interchangeable. An insurer might cover a medicine only after another treatment fails. A hospital might receive payment for the drug but struggle to recover the cost of administering it. Both situations restrict access without necessarily changing the manufacturer’s published price.
| Decision | Practical question | Investment implication |
|---|---|---|
| Regulatory approval | Can the medicine be marketed for the approved use? | Defines the permitted commercial opportunity, not guaranteed payment. |
| Pricing | What is charged before and after concessions? | Determines potential revenue per paid treatment. |
| Coverage | Which patients qualify for insurer funding? | Can narrow the commercially reachable population. |
| Reimbursement | How much is paid, to whom and through which process? | Affects provider participation and payment timing. |
| Practical access | Can patients complete the steps needed to receive treatment? | Determines how much funded demand becomes actual use. |
Keep the approval decision separate from the payer decision throughout the analysis. The FDA and EMA approval processes assess the evidence needed to permit marketing; commercial forecasts must then address funding and treatment delivery. A broad approved indication creates room for sales, but a model should not assume every patient within that indication receives equally straightforward access. Treat approval as the starting boundary for the forecast, then document the coverage rules and delivery requirements that narrow it.
From List Price to Manufacturer Net Revenue
The list price is a reference point, not a reliable estimate of revenue per patient. Manufacturers may provide negotiated rebates, government program concessions, distribution discounts and other allowances. Some deductions occur through the supply chain, others after the original sale. The difference between gross sales and reported net sales is often called the gross-to-net deduction. Its composition matters. A change in the mix of payers can alter revenue per treatment even when the published price remains unchanged. Investors should therefore distinguish a price increase from an improvement in the amount the manufacturer retains.
Revenue deductions also involve estimates. Vertex Pharmaceuticals’ 2025 financial reporting describes estimating rebates, chargebacks and discounts using payer contracts, government requirements, payer mix and historical experience. Those estimates are adjusted as further information becomes available. This provides a useful reason to read the revenue recognition notes rather than relying on a product sales headline alone: reported net revenue reflects assumptions about obligations that may settle later. The relevant disclosures appear in Vertex’s 2025 Form 10-K.
An Illustrative Price Waterfall
Consider a hypothetical chronic medicine with an annual list price of $120,000 for a full year of treatment. The following figures are assumptions, not industry averages or estimates for an actual product. They represent weighted deductions across a hypothetical sales mix. Different rebates should not be stacked onto every prescription indiscriminately; the applicable deductions depend on the transaction and payer arrangement.
| Item | Illustrative annual amount |
|---|---|
| Gross revenue at list price | $120,000 |
| Negotiated rebates and government concessions | −$30,000 |
| Distribution discounts and revenue-related fees | −$3,000 |
| Returns and other revenue allowances | −$3,000 |
| Manufacturer net revenue | $84,000 |
| Total gross-to-net deduction | 30% |
At 1,000 full paid patient years, this example produces $84 million in net revenue, not $120 million. That is still revenue, not profit. Manufacturing costs, medical affairs, sales operations and other expenses remain to be paid. For an investor, the useful discipline is to maintain separate assumptions for list price, deductions and treatment volume. Combining them into one unexplained “revenue per patient” figure makes it harder to identify why a forecast changes.
Who Controls Access in the United States?
Health Plans and Pharmacy Benefit Managers
Health plans fund covered care under their benefit arrangements. Pharmacy benefit managers, or PBMs, perform functions that can include negotiating manufacturer rebates, administering pharmacy benefits and developing formularies, the lists of covered drugs. Rebate contracts can connect manufacturer concessions with favourable formulary placement, although the terms and distribution of those payments vary. The FTC’s July 2024 report on PBM contracting documents these relationships. For investment analysis, the question is whether a concession buys commercially useful access. A lower net price may be worthwhile if it produces enough additional paid treatment; a rebate that leaves substantial restrictions in place deserves closer examination.
Assess bargaining power against the available alternatives. A medicine with a persuasive advantage over current treatment presents a different negotiating proposition from one offering modest convenience at a much higher cost. However, avoid assigning a price premium simply because management calls the product differentiated. Establish what patients and payers gain, whether that gain is supported by comparative evidence, and how readily another treatment could serve the same patients. The relevant work belongs alongside an assessment of standards of care and competing pipelines.
The Benefit Category Changes the Payment Route
A drug taken at home and a drug administered in a treatment centre may follow different payment routes. Medicare provides a useful example: Part B covers certain outpatient drugs under defined conditions, including many drugs patients do not usually administer themselves, while Part D covers many prescription medicines that Part B does not cover. The distinction is set out in Medicare’s outpatient prescription drug coverage rules. Do not turn this into a universal rule that every infused medicine follows one route and every oral medicine another. Check the product, setting and benefit. The commercial model needs to identify who purchases the drug, who submits the claim and who carries the financial exposure before reimbursement arrives.
Medicare Negotiation and Medicaid Rebates
Medicare negotiation is now an operating consideration, rather than a distant policy possibility. Negotiated maximum fair prices for the first ten selected Part D drugs took effect on January 1, 2026. The program applies to selected products; it does not establish one negotiated price for every newly approved medicine. When assessing the effect of a negotiated price, compare it with the relevant previous net price, not just the list price. A large headline discount from list can overstate the incremental revenue change if substantial rebates already existed. The original prices and implementation terms are documented in the CMS fact sheet on 2026 negotiated prices.
Medicaid introduces another pricing mechanism. For many innovator drugs, the statutory rebate calculation incorporates average manufacturer price, best price and an inflation adjustment; other drug categories have different formulas. The Medicaid unit rebate calculation rules show why one assumed commercial discount cannot represent every payer channel. A product’s payer mix should therefore appear explicitly in the forecast. If the expected patient population has substantial Medicaid coverage, commercial insurance assumptions are a poor substitute for analysing the relevant government program economics. Avoid inferring manufacturer revenue from a patient’s small copayment, too. Those are different amounts.
Why Covered Patients May Still Struggle to Start Treatment
Coverage Can Carry Restrictive Conditions
A formulary listing does not tell the whole access story. Prior authorisation requires approval against the plan’s criteria before coverage is granted. Step therapy requires patients to try another treatment first, subject to applicable exceptions. Quantity limits restrict how much medicine the plan covers within a period. These mechanisms are described in Medicare’s prescription drug plan rules. When reviewing an access announcement, examine the underlying policy: which disease severity qualifies, what previous treatment is required, and what documentation the prescriber must submit. “Covered” is too broad a label to support a patient forecast without those details.
This is where a disease population must become a commercially reachable population. Start with the approved indication, then identify the patients meeting the actual funding conditions. Do not count the same restriction twice. If a forecast has already removed patients who fail a payer’s severity requirement, it should not apply another broad access discount that repeats that exclusion. A clear addressable market estimate records each filter, its evidence and the remaining patient count. The resulting number may be smaller than management’s headline opportunity, but it is more useful.
Patient Costs and Treatment Logistics Remain Separate Barriers
Manufacturer net price, insurer spending and patient out-of-pocket cost should occupy separate lines in the analysis. They answer different questions. A forecast can assume acceptable payer economics yet still require evidence that patients can afford their share. Administrative delays, missing documents and the need to coordinate appointments also belong in the treatment pathway. Rather than inserting an unexplained haircut, map the steps from prescription to first paid treatment. Then assess where patients could stop or wait. The operational evidence becomes part of evaluating drug launches and patient adoption.
For a hospital-administered treatment, test the provider’s economics separately from the manufacturer’s. The model should ask whether reimbursement covers acquisition, administration and associated care, and how much cash the provider must commit before receiving payment. It should also test staffing, treatment slots and referral capacity. These are due diligence questions, not reasons to assume every launch will be slow. A favourable answer needs evidence. Production and delivery constraints require their own review under biotech manufacturing and capacity analysis, rather than being buried inside a pricing assumption.
What Evidence Supports a Drug’s Price?
Clinical Benefit Must Connect to the Payer’s Decision
Build the pricing case around the treatment’s incremental benefit over the relevant alternative. Does it improve survival, reduce symptoms, prevent complications or reduce the burden of care? How durable is the benefit, and what uncertainty remains? A statistically positive result is not enough to quantify a price premium. Translate the evidence into outcomes that matter for the proposed use, without assuming that every measured change produces an economic saving. The distinction between a trial measurement and a patient benefit is central to interpreting clinical endpoints.
Comparative evidence deserves particular attention. A trial can answer its own research question convincingly while leaving uncertainty about how the medicine compares with current practice. Check the control treatment, the enrolled population and the timing of the study. If the pricing argument depends on superiority to an alternative that was not tested directly, identify the assumptions needed to make that comparison. Do not present an indirect estimate as a head-to-head result. Those questions connect pricing research with the assessment of clinical trial design and patient selection.
Cost Effectiveness and Budget Impact Answer Different Questions
Cost effectiveness concerns whether additional health benefits justify additional costs relative to alternatives. One approach measures health gains in quality adjusted life years, or QALYs, which combine survival and health-related quality of life. The incremental cost effectiveness ratio divides additional total cost by additional QALYs. NICE’s appraisal methods use this framework and require a time horizon long enough to capture relevant differences between treatments. The details are set out in the NICE economic evaluation manual. The drug’s acquisition price is therefore one input, alongside treatment outcomes and other healthcare resource use.
Budget impact asks a more immediate question: what would adoption cost the payer over the period being planned? Consider a hypothetical treatment that adds $20,000 in annual net spending for each patient. At 500 patients, that is $10 million; at 50,000 patients, $1 billion. The calculation says nothing by itself about value for money. It shows why population size and uptake matter alongside the benefit per patient. In a forecast, keep the long-term value argument separate from the near-term funding requirement. A persuasive model should make both visible.
How European Market Access Differs
European clinical assessment should not be mistaken for a single European reimbursement decision. Under the EU health technology assessment framework, joint clinical assessments began applying from January 12, 2025, to new cancer medicines and advanced therapy medicinal products within scope. The assessments support national processes by analysing relative clinical effects. They do not themselves grant a common European price or funded patient population. The European Commission’s joint clinical assessment framework describes the scope and process. For investors, revenue should therefore be built country by country, with separate assumptions for access timing, price and adoption, rather than assigning one European launch date.
Published prices may also reveal less than they appear to. In England, NICE processes allow confidential simple discount patient access schemes and other commercial arrangements, with rules governing what is disclosed publicly. A public appraisal can therefore support a treatment’s use without revealing the exact price used in the economic assessment. The NICE rules on commercial arrangements and confidentiality explain this distinction. When estimating revenue, do not treat an undisclosed discount as zero or invent a precise figure. Use a reasoned range and show how the valuation changes across it.
Outcomes-Based Agreements and One-Time Therapies
Outcomes-based contracts connect some payment to measured patient results. A real example is the CMS Cell and Gene Therapy Access Model, which includes arrangements for Casgevy and Lyfgenia for eligible Medicaid patients with sickle cell disease. Under the model, manufacturers reimburse the payer for part of the treatment payment when outcomes fall short of the agreed expectations; agreements may also include other concessions. The CMS explanation of its gene therapy payment agreements sets out the mechanism. These contracts should not be described simply as a high price paid in full, nor as a guarantee that all treatment risk has transferred to the manufacturer.
Evaluate the contract’s economics through its actual terms. Which outcome triggers a rebate? When is it measured? What happens if follow-up data are missing? A payment spread over time addresses the timing of expenditure; a performance-linked refund addresses uncertainty about results. They are different arrangements, even when combined. For investors in gene therapy businesses, test treatment durability, potential refunds and collection timing separately. Also distinguish an initial pool of previously untreated patients from the flow of newly eligible patients. A large opening opportunity does not establish recurring annual demand at the same level.
Build Pricing and Access Into the Same Revenue Model
A useful starting equation for a chronic medicine is:
Net product revenue = paid treatment starts × average paid treatment duration within the year × annualised net price.
This is a modelling structure, not an accounting rule. The definitions must remain consistent. If the forecast uses average patients receiving paid treatment across the year, duration may already be reflected in that average. Applying a further duration adjustment would undercount revenue. For a one-time therapy, paid administrations may be the more appropriate volume measure. Before adding detail, establish what one unit in the model represents. That makes later valuation sensitivity testing much easier to interpret.
An Illustrative Access and Revenue Forecast
Assume a hypothetical medicine has 12,000 diagnosed patients in the territory being modelled. Of these, 8,000 meet its approved indication and 5,000 have a viable funded treatment pathway. The base case assumes 1,500 paid starts, equivalent to 30% of that reachable group. Average paid treatment within the forecast year is nine months, reflecting when patients start and when some stop. Using the earlier illustrative annual net price of $84,000 produces $94.5 million in revenue. Every figure here is an assumption, not an estimate for an actual medicine.
| Assumption | Downside | Base case | Higher adoption case |
|---|---|---|---|
| Paid treatment starts | 1,000 | 1,500 | 2,000 |
| Average paid treatment within the year | 0.50 years | 0.75 years | 0.85 years |
| Annualised manufacturer net price | $72,000 | $84,000 | $90,000 |
| Illustrative net revenue | $36 million | $94.5 million | $153 million |
The higher adoption case deliberately combines favourable assumptions, so it needs a stronger explanation than “execution improves.” Broader access may require greater concessions, reducing net price. Earlier starts can increase paid treatment time within a year without improving persistence. Longer treatment can reflect better retention, or simply a different mix of patients. Test these relationships rather than allowing every variable to improve independently. The resulting cash flows can then feed into a risk-adjusted pipeline valuation, with commercial uncertainty kept distinct from clinical and regulatory risk.
Payment Timing and Price Durability
A revenue forecast also needs a cash collection schedule. Separate the date of treatment, the recognition of revenue, the settlement of concessions and the receipt of cash. For a hypothetical launch, a six-month delay in collections would create a different funding requirement from immediate payment, even if eventual revenue were identical. Model the working capital requirement explicitly rather than assuming revenue funds operations as soon as it appears in the income statement. This is particularly relevant when assessing cash burn and runway for a company financing its first commercial product.
Do not hold launch economics constant for the entire product life without testing why they should persist. Build alternative paths for net price, payer restrictions and competing treatment costs. The arrival of a cheaper alternative may affect the pricing argument before it removes all demand for the original medicine. The timing and nature of that competition require separate work on patent expiry, generics and biosimilars. A model should show the proposed mechanism of erosion, not apply a sudden arbitrary percentage cut simply because a calendar date has arrived.
What to Check in Company Disclosures
Translate broad management statements into questions that can be checked against documents. If a company reports access to a percentage of covered lives, establish the denominator, the relevant indication and whether the measure includes restrictive policies. Covered lives count insured members, not patients who have obtained approval or begun paid treatment. If management reports patient starts, determine whether these include free supply or other arrangements that differ from ordinary paid use. Neither metric is useless. Each needs a definition before it can support a sales forecast.
- Coverage evidence: Review dated payer policies, including eligibility requirements and previous treatment rules.
- Pricing evidence: Separate published prices from disclosed net revenue and explain any estimated deductions.
- Treatment evidence: Distinguish referrals, prescriptions, approved patients and paid administrations.
- Financial evidence: Read revenue recognition, rebate estimates, receivables and relevant contract disclosures.
- Economic evidence: Check the comparator, treatment duration and assumptions behind claimed cost offsets.
Keep an evidence record showing the document, publication date, geographic scope and model assumption it supports. The discipline used in researching biotech through filings and primary records applies just as much to market access as to clinical development. Where a net price, contract term or approval conversion rate is undisclosed, label it as an estimate. Set a range, identify what future disclosure could narrow it, and avoid giving an uncertain input more decimal places than the evidence deserves.